Search hospitals

>

Manitoba

>

WINNIPEG

CancerCare Manitoba

Claim this profile

WINNIPEG, Manitoba R3E 0V9

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Brain Tumor

Conducts research for Leukemia

Conducts research for Lymphoma

433 reported clinical trials

19 medical researchers

Photo of CancerCare Manitoba in WINNIPEGPhoto of CancerCare Manitoba in WINNIPEGPhoto of CancerCare Manitoba in WINNIPEG

Summary

CancerCare Manitoba is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Cancer, Breast Cancer, Brain Tumor, Leukemia, Lymphoma and other specialties. CancerCare Manitoba is involved with conducting 433 clinical trials across 439 conditions. There are 19 research doctors associated with this hospital, such as Ashley Chopek, Issai M. Vanan, Versha Banerji, and Kristjan Paulson.

Area of expertise

1

Cancer

Global Leader

CancerCare Manitoba has run 46 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Breast Cancer

Global Leader

CancerCare Manitoba has run 42 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at CancerCare Manitoba

Cancer

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Testicular cancer

Acute Myelogenous Leukemia

Wilms Tumor

Myelodysplastic Syndrome

Breast Cancer

Neuroblastoma

Lymphoma

Image of trial facility.

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Sarcoma

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.

Recruiting

2 awards

Phase 3

10 criteria

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at CancerCare Manitoba?

Where is CancerCare Manitoba located?

Who should I call to ask about financial aid or insurance network?

What insurance does CancerCare Manitoba accept?

What awards or recognition has CancerCare Manitoba received?